Amgen today announced that the U.S. Food and Drug Administration has approved LUMAKRAS ™ for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test, who have received at least one prior systemic therapy. LUMAKRAS has received accelerated approval based on overall response rate and duration of response . Continued .
Amgen (AMGN) Confirms FDA Approves LUMAKRAS (Sotorasib) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of.
Higher CD8 T cells may influence COVID-19 recovery in blood cancer patients
Antibodies aren t the only immune cells needed to fight off COVID-19 -; T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in
Nature Medicine. The researchers found that blood cancer patients with COVID-19 who had higher CD8 T cells, many of whom had depleted antibodies from cancer treatments, were more than three times likelier to survive than patients with lower levels of CD8 T cells.
It s clear T cells are critical in terms of the early infection and to help control the virus, but we also showed that they can compensate for B cell and antibody responses, which blood cancer patients are likely missing because of the drugs. This is important when we think about how to improve the care of cancer patients with COVID. We need to maximize all the arms of the immune system, especially if